Microencapsulated umbilical cord Wharton Jelly-derived human mesenchymal stem cells for the cell therapy of type 1 diabetes mellitus (T1d): applications and limits

CellR4 2017; 5 (6): e2467

  Topic: Diabetes, Stem cell     Category:

Abstract

We aimed to blunt islet β-cell directed autoimmune aggression as a potential approach for the treatment of Type 1 Diabetes (T1D). For this purpose, we proposed the use of a particular type of Mesenchymal Stem Cells, retrieved from the post-partum umbilical cord Wharton Jelly (hUCMS). To maximize hUCMS immunomodulatory potential, that has been proven impaired by cell-to-cell contact, we encapsulated these cells within highly purified, alginate-based microcapsules. Encapsulation enabled physical isolation of the cells from the host’s immune system.

Pilot in vitro experiments where microencapsulated hUCMS were co-incubated with PBMCs derived from T1D patients showed induction of Treg and rebalance of Th1/Th2 cells. In vivo studies in diabetic NOD mice showed that microencapsulated hUCMS yield long-term remission of hyperglycemia. Use of the encapsulated hUCMS showed that in cell-based immunomodulatory strategies, the transplanted cells can benefit from encapsulation. It is likely that such immune-therapeutic approach could have efficacy only if residual native β-cell mass is still present. Otherwise, hUCMS-induced rehabilitation of the immune system would be unable to grant for reversal of diabetes. The proposed method, employing hUCMS in alginate microcapsules, presents a good safety and efficacy profile. This could warrant initiation of pilot human clinical trials of microencapsulated hUCMS grafts patients with recent-onset T1D.

To cite this article

Microencapsulated umbilical cord Wharton Jelly-derived human mesenchymal stem cells for the cell therapy of type 1 diabetes mellitus (T1d): applications and limits

CellR4 2017; 5 (6): e2467

Publication History

Submission date: 25 Oct 2017

Revised on: 06 Nov 2017

Accepted on: 21 Nov 2017

Published online: 30 Nov 2017